Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Assets (2016 - 2025)

Historic Assets for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $372.7 million.

  • Cartesian Therapeutics' Assets fell 1815.03% to $372.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.7 million, marking a year-over-year decrease of 1815.03%. This contributed to the annual value of $435.0 million for FY2024, which is 4260.71% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Assets of $372.7 million as of Q3 2025, which was down 1815.03% from $388.9 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Assets ranged from a high of $455.3 million in Q3 2024 and a low of $106.0 million during Q3 2023
  • Over the past 5 years, Cartesian Therapeutics' median Assets value was $180.5 million (recorded in 2021), while the average stood at $252.8 million.
  • In the last 5 years, Cartesian Therapeutics' Assets plummeted by 4051.89% in 2023 and then soared by 32940.57% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Assets (Quarter) stood at $159.9 million in 2021, then grew by 3.75% to $165.9 million in 2022, then soared by 83.89% to $305.0 million in 2023, then surged by 42.61% to $435.0 million in 2024, then fell by 14.33% to $372.7 million in 2025.
  • Its last three reported values are $372.7 million in Q3 2025, $388.9 million for Q2 2025, and $409.1 million during Q1 2025.